Research programme: siRNA kidney disorder therapeutics - Quark Pharmaceuticals

Drug Profile

Research programme: siRNA kidney disorder therapeutics - Quark Pharmaceuticals

Alternative Names: PFTi

Latest Information Update: 06 Sep 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Quark Biotech
  • Developer Quark Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Renal failure

Most Recent Events

  • 06 Sep 2010 No development reported - Preclinical for Renal failure in USA (IV)
  • 14 Oct 2008 Preclinical development is ongoing in USA
  • 19 Dec 2006 Preclinical trials in Renal failure in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top